| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRNEPH.2010.34 |
| P698 | PubMed publication ID | 20234355 |
| P2093 | author name string | Mark D Stegall | |
| James Gloor | |||
| P2860 | cites work | Rituximab therapy for acute humoral rejection after kidney transplantation | Q80318231 |
| The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome | Q80389325 | ||
| Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year | Q80470291 | ||
| C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients | Q81180697 | ||
| Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies | Q81414156 | ||
| Peritubular capillary damage in acute humoral rejection: an ultrastructural study on human renal allografts | Q81515287 | ||
| The virtual crossmatch--a screening tool for sensitized pediatric heart transplant recipients | Q82654389 | ||
| Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation | Q82732578 | ||
| Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies | Q83150706 | ||
| The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 | ||
| Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 | ||
| Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. | Q33542619 | ||
| Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. | Q33812395 | ||
| Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications | Q33814460 | ||
| Accommodation: preventing injury in transplantation and disease | Q34315248 | ||
| Multiple myeloma. | Q34362643 | ||
| Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial | Q34373536 | ||
| Immunoadsorption with protein A in humoral rejection of kidney transplants | Q34663036 | ||
| On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants | Q35025834 | ||
| Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications | Q35142598 | ||
| Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation | Q35766497 | ||
| Proteasome inhibition as a novel therapeutic target in human cancer. | Q36014046 | ||
| Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection | Q36078696 | ||
| B cells: a rational target in alloantibody-mediated solid organ transplantation rejection | Q36429791 | ||
| Manipulating the Immune System with Immune Globulin | Q36725772 | ||
| Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies | Q36736625 | ||
| The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection | Q36772871 | ||
| 14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation | Q36795985 | ||
| Identification of a receptor required for the anti-inflammatory activity of IVIG. | Q37018736 | ||
| The spectrum of antibody-mediated renal allograft injury: implications for treatment | Q37176570 | ||
| Role of anti-MHC class I antibody in facilitating transplant accommodation | Q37407686 | ||
| Mechanisms of alloantibody production in sensitized renal allograft recipients | Q37473459 | ||
| Intravenous immunoglobulin a natural regulator of immunity and inflammation | Q37544139 | ||
| Renal transplantation and B-cell cross-matches with autoantibodies and alloantibodies | Q39463299 | ||
| Immunoglobulin G dimer: an idiotype-anti-idiotype complex | Q39708167 | ||
| Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. | Q40673462 | ||
| Flow cytometric detection of HLA antibodies using a spectrum of microbeads | Q40907524 | ||
| Flow cytometry in the transplant laboratory | Q40907973 | ||
| Intertubular capillary changes in kidney allografts: an ultrastructural study in patients with transplant glomerulopathy | Q43775702 | ||
| The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients | Q43856835 | ||
| Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. | Q44092564 | ||
| Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients | Q44584357 | ||
| Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations | Q44762236 | ||
| Rituximab as treatment for refractory kidney transplant rejection | Q44899030 | ||
| Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin | Q44913849 | ||
| Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification | Q44919347 | ||
| Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution | Q45185527 | ||
| Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab | Q45230226 | ||
| Positive cross-match living donor kidney transplantation: longer-term outcomes | Q46134337 | ||
| HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway | Q46142365 | ||
| Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience | Q46155740 | ||
| Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation | Q46270876 | ||
| Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production | Q46270888 | ||
| Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ | Q46321287 | ||
| Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 | ||
| Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience | Q46486893 | ||
| National conference to assess antibody-mediated rejection in solid organ transplantation | Q47347260 | ||
| Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. | Q47726666 | ||
| Significance of the positive crossmatch test in kidney transplantation | Q47800073 | ||
| No advantage of flow cytometry crossmatch over complement-dependent cytotoxicity in immunologically well-documented renal allograft recipients | Q47816053 | ||
| Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 | ||
| HLA antibody identification with single antigen beads compared to conventional methods. | Q51303028 | ||
| Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. | Q51789761 | ||
| Transplanting the highly sensitized patient: The emory algorithm. | Q51934409 | ||
| Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. | Q53506317 | ||
| Transplant glomerulopathy: subclinical incidence and association with alloantibody. | Q53543179 | ||
| Kidney transplantation in patients with antibodies against donor HLA class II. | Q53571597 | ||
| The effect of desensitization protocols on human splenic B-cell populations in vivo. | Q53575915 | ||
| A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. | Q53639822 | ||
| Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. | Q53659700 | ||
| Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. | Q53965909 | ||
| Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. | Q54013696 | ||
| Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. | Q54380136 | ||
| Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. | Q55034268 | ||
| Overcoming a positive crossmatch in living-donor kidney transplantation. | Q55036659 | ||
| The Banff 97 working classification of renal allograft pathology | Q59314413 | ||
| Immediate rejection of a HLA-A, B compatible, HLA-DR incompatible kidney with a positive donor-recipient B-cell crossmatch | Q67295081 | ||
| The effects of antibodies on human renal allografts | Q67485054 | ||
| Removal of lymphocytotoxic antibodies by pretransplant immunoadsorption therapy in highly sensitized renal transplant recipients | Q68196123 | ||
| Hyperacute and acute kidney graft rejection due to antibodies against B cells | Q68209607 | ||
| Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches. Relationship to renal transplant outcome | Q68920536 | ||
| Antiidiotypic suppression of autoantibodies with normal polyspecific immunoglobulins | Q69202995 | ||
| Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation | Q69366948 | ||
| Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome | Q69401035 | ||
| Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells | Q70067993 | ||
| Transfusion-induced alloimmunization in patients awaiting renal allografts | Q70399633 | ||
| Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema | Q71157326 | ||
| Variations of the lymphocytotoxicity test. An evaluation of sensitivity and specificity | Q72063303 | ||
| Specificity and Ig class of preformed alloantibodies causing a positive crossmatch in renal transplantation. The implications for graft survival | Q72092195 | ||
| B cell antibodies and crossmatching | Q72128872 | ||
| Capillary deposition of C4d complement fragment and early renal graft loss | Q72791721 | ||
| Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells | Q73041725 | ||
| A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants | Q73299691 | ||
| Antibody-mediated rejection of human renal allografts: an electron microscopic study of peritubular capillaries | Q73416407 | ||
| Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg) | Q74815832 | ||
| Ligation of HLA class I molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression and cell proliferation | Q77457124 | ||
| Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation | Q77736829 | ||
| Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching | Q77781397 | ||
| Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients | Q79347382 | ||
| Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial | Q79364646 | ||
| Successful rescue of refractory, severe antibody mediated rejection with splenectomy | Q79552624 | ||
| Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts | Q79576266 | ||
| Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation | Q79741109 | ||
| Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN') | Q79921621 | ||
| Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival | Q80054535 | ||
| Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine | Q80068380 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 297-306 | |
| P577 | publication date | 2010-03-16 | |
| P1433 | published in | Nature Reviews Nephrology | Q2079275 |
| P1476 | title | Sensitized renal transplant recipients: current protocols and future directions | |
| P478 | volume | 6 |
| Q36688282 | A glow of HLA typing in organ transplantation |
| Q39105369 | Acute antibody-mediated rejection in kidney transplant recipients |
| Q36687017 | Allocating Deceased Donor Kidneys to Candidates with High Panel-Reactive Antibodies |
| Q35083760 | Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice. |
| Q37058043 | Banff 2011 Meeting report: new concepts in antibody-mediated rejection |
| Q36919516 | Challenges in organ transplantation |
| Q39009557 | Chronic allograft injury: Mechanisms and potential treatment targets |
| Q104802057 | Clinical and Pathologic Feature of Patients With Early Versus Late Active Antibody-Mediated Rejection After Kidney Transplantation: A Single-Center Experience |
| Q51322272 | Comparison of paired exchange kidney transplantations with living related kidney transplantations. |
| Q40749159 | Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection. |
| Q37391506 | Detection of IgG antibodies to donor specific HLA class I & II antigens in post renal transplant cases |
| Q38001495 | Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe? |
| Q99571437 | Double-Filtration Plasmapheresis Plus Low-Dose Anti-thymocyte Globulin and Tacrolimus in Asian Living-Donor Kidney Transplantation With Donor-Specific Anti-HLA Antibody |
| Q52888455 | Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation. |
| Q85485720 | Effects of mycophenolic acid on highly sensitized patients awaiting kidney transplant |
| Q47828312 | First International Paired Exchange Kidney Transplantations of Turkey. |
| Q37778273 | Immunosuppression in the sensitized heart transplant recipient |
| Q38036246 | Incompatible kidney transplantation: a brief overview of the past, present and future. |
| Q38006827 | Innovative strategies in living donor kidney transplantation |
| Q87233834 | Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results |
| Q46436844 | Intravenous human immunoglobulin treatment of serum from HLA-sensitized patients in kidney transplantation |
| Q84999226 | Kidney Paired Donation in Live-Donor Kidney Transplantation |
| Q52310243 | Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. |
| Q87599320 | Kidney transplantation across a positive crossmatch: a single-center experience |
| Q38658621 | Kidney transplantation, bioengineering and regeneration: an originally immunology-based discipline destined to transition towards ad hoc organ manufacturing and repair. |
| Q38032838 | Living donor kidney paired donation transplantation: experience as a founding member center of the National Kidney Registry |
| Q53158985 | Long-term histopathology of allografts in sensitized kidney recipients. |
| Q37446883 | New immunosuppressive agents in pediatric transplantation |
| Q38102315 | New perspectives of immunosuppression. |
| Q42229870 | Outcome comparison of ABO-incompatible kidney transplantation with low-dose rituximab and ABO-compatible kidney transplantation: a single-center experience. |
| Q38665933 | Outcome of Pretransplantation Therapeutic Plasma Exchange in Highly Sensitized Deceased-donor Kidney Transplant Recipients. |
| Q34241347 | Persistence of recipient human leucocyte antigen (HLA) antibodies and production of donor HLA antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation |
| Q39289605 | Renal transplantation in sensitized children and young adults: a nationwide approach |
| Q44846201 | Single-center kidney paired donation: the Methodist San Antonio experience |
| Q42283383 | Successful kidney transplantation across a positive complement-dependent cytotoxicity crossmatch by using C1q assay-directed, bortezomib-assisted desensitization: A case report |
| Q36072165 | The major histocompatibility complex in transplantation |
| Q82064319 | The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients |
| Q38205229 | Transplant glomerulopathy: the interaction of HLA antibodies and endothelium |
Search more.